The Role of Nicotinamide Mononucleotide Supplementation in Psoriasis Treatment

Zhengyi Zhang,Baochen Cheng,Wenqian Du,Mengqi Zeng,Ke He,Tingyi Yin,Sen Shang,Tian Su,Dan Han,Xinyi Gan,Ziyang Wang,Meng Liu,Min Wang,Jiankang Liu,Yan Zheng

DOI: https://doi.org/10.3390/antiox13020186

IF: 7.675

2024-02-01

Antioxidants

Abstract:Psoriasis is one of several chronic inflammatory skin diseases with a high rate of recurrence, and its pathogenesis remains unclear. Nicotinamide mononucleotide (NMN), as an important precursor of nicotinamide adenine dinucleotide (NAD+), has been reported to be a promising agent in treating various diseases, its positive effects including those induced via its anti-inflammatory and antioxidant properties. For this reason, we have aimed to explore the possible role of NMN in the treatment of psoriasis. Psoriasis models were constructed with imiquimod (IMQ) stimulation for 5 days in vivo and with M5 treatment in keratinocyte cell lines in vitro. NMN treatment during the IMQ application period markedly attenuated excess epidermal proliferation, splenomegaly, and inflammatory responses. According to GEO databases, Sirtuin1 (SIRT1) levels significantly decreased in psoriasis patients' lesion tissues; this was also the case in the IMQ-treated mice, while NMN treatment reversed the SIRT1 decline in the mouse model. Moreover, NMN supplementation also improved the prognoses of the mice after IMQ stimulation, compared to the untreated group with elevated SIRT1 levels. In HEKa and HaCaT cells, the co-culturing of NMN and M5 significantly decreased the expression levels of proinflammation factors, the phosphorylation of NF-κB, stimulator of interferon genes (STING) levels, and reactive oxygen species levels. NMN treatment also recovered the decrease in mitochondrial membrane potential and respiration ability and reduced mtDNA in the cytoplasm, leading to the inhibition of autoimmune inflammation. The knockdown of SIRT1 in vitro eliminated the protective and therapeutic effects of NMN against M5. To conclude, our results indicate that NMN protects against IMQ-induced psoriatic inflammation, oxidative stress, and mitochondrial dysfunction by activating the SIRT1 pathway.

biochemistry & molecular biology,chemistry, medicinal,food science & technology

What problem does this paper attempt to address?

This paper aims to explore the potential role of nicotinamide mononucleotide (NMN) in the treatment of psoriasis. Specifically, the researchers constructed mouse psoriasis models stimulated with imiquimod (IMQ) and keratinocyte cell line models to evaluate the effect of NMN on psoriasis symptoms. The main objective of the study was to explore whether NMN could alleviate IMQ - induced psoriasis inflammation, oxidative stress and mitochondrial dysfunction by activating the Sirtuin1 (SIRT1) pathway.

The paper attempts to solve the problem in the following aspects:

1. **Cell viability and inflammatory response**: The study first evaluated the effect of different concentrations of NMN on the viability of human keratinocytes (HEKa and HaCaT cells), and observed the inhibitory effect of NMN co - treated with M5 (a mixed cytokine used to simulate the psoriasis environment) on cell viability and inflammatory response.

2. **Mouse model experiments**: By orally and topically administering NMN, the study investigated its symptom - improving effects on IMQ - induced psoriasis mouse models, including the alleviation of symptoms such as skin erythema and thickening, as well as the mitigation of body weight loss in mice.

3. **Discussion of molecular mechanisms**: By detecting changes in relevant proteins (such as p - NF - κB, STING, etc.) and mRNA levels, the study explored how NMN inhibits the inflammatory response, reduces oxidative stress, and improves mitochondrial function by activating the SIRT1 pathway.

In summary, this paper attempts to experimentally verify the potential efficacy of NMN in the treatment of psoriasis and its mechanism of action, especially by activating the SIRT1 pathway to achieve the above effects.